Formulation, Optimization And Characterization Of Nanostructured Lipid Carrier Of Nitrofurantoin

Nitrofurantoin is effective against many urinary tract pathogens. It acts as bacteriostatic and/or bactericidal by inhibiting DNA-RNA protein& cell wall synthesis. Nanostructured Lipid Carriers (NLCs) of NFT was prepared by Hot Homogenization Process. Glyceryl Monostearate and Miglyol 812 were heated at 80ºC temperature on hot plate. In the melted lipid, drug was added with continuous stirring at high speed homogenization. Formulation NLC12B has % Entrapment efficiency 89.1 ± 0.5, PDI 0.11 ± 0.01 and mean particle size 237 ± 7nm represents narrow particle size distribution. Spherical feature of NLCs with better uniformity without aggregation of Nitrofurantoin loaded NLC was confirmed by TEM. Moreover, efficient miscibility of drug in lipids was confirmed by the absence of intense and characteristic peak of NFT in XRPD. After 6 month storage at 2-8°C there was no significant changes in the PDI as well as mean particle size.

Tear glucose estimation--an alternative to blood glucose estimation.

Dextrostix, being very sensitive to measure glucose level by glucose oxidase method, was chosen to measure tear glucose level to evaluate the relationship of tear glucose to blood glucose level in 94 cases. It was found that in our population the measurement of tear glucose has definite value in interpretation of glucose status of individual. So, it was suggested to use this simple method of detection of tear glucose to interpret hyperglycaemic state of the patients. The present study was undertaken (1) to sort out a definite relationship between tear and plasma glucose concentration and (2) to devise a rapid method for detection of tear glucose level semiquantitatively with glucose oxidase impregnated strips and to evaluate its role as indicator of plasma glucose level.

Uterine and placental 5-HT profile in different gestational period of albino rats.

Possible role of 5-HT in pregnancy was investigated in albino rats by biological estimation of uterine and placental 5-HT contents in different periods of gestation in normal and drug treated rats. Uterine 5-HT level increased steadily from day-1 of gestation to reach the peak on day-7; thereafter, the level continued to decline throughout the period till day-20 when 5-HT level was lowest. From day-20, a mild secondary rise started and remained persistent even after parturition. The results show that a critical level of 5-HT in early gestational period is necessary for conception. Manipulation of endogenous 5-HT do not influence duration of gestation.